Payment overview · 2025
General Payments
$469.01
23 reported records · 12 companies
Healthcare provider profile · identity verified
Mohammed Antwi, P.A.-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · FORT WORTH, TX · NPI 1356442321
Verified facts
What the public records show
CMS Open Payments records show Mohammed Antwi, P.A.-C received $469.01 in general payments during 2025 across 23 reported records.
Inspire Medical Systems, Inc. accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $70.89 | 15.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.77 | 14.7% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $64.28 | 13.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.28 | 13.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $42.18 | 9.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.26 | 7.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.46 | 6.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.20 | 5.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.62 | 4.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.93 | 4.0% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $17.34 | 3.7% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $15.80 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $424.01 | 22 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $70.89 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $64.28 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.59 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $42.18 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.26 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.46 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $21.62 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 53 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 287 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 247 | 90 |
| Lisinopril | Lisinopril | 228 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 198 | 69 |
| Metformin Hcl | Metformin Hcl | 146 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 137 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 45 |
| Losartan Potassium | Losartan Potassium | 123 | 42 |
| Gabapentin | Gabapentin | 116 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 49 |
| Omeprazole | Omeprazole | 85 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 84 | 31 |
| Trazodone Hcl | Trazodone Hcl | 74 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 32 |
| Furosemide | Furosemide | 69 | 31 |
| Amoxicillin | Amoxicillin | 63 | 57 |
| Montelukast Sodium | Montelukast Sodium | 58 | 18 |
| Carvedilol | Carvedilol | 55 | 24 |
| Eliquis | Apixaban | 53 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 18 |
| Meloxicam | Meloxicam | 52 | 19 |
| Allopurinol | Allopurinol | 51 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 49 | 19 |
| Simvastatin | Simvastatin | 49 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 47 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 17 |
| Alendronate Sodium | Alendronate Sodium | 44 | 13 |
| Sertraline Hcl | Sertraline Hcl | 43 | 16 |
| Prednisone | Prednisone | 42 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 17 |
| Jardiance | Empagliflozin | 40 | 15 |
| Mirtazapine | Mirtazapine | 39 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 11 |
| Ozempic | Semaglutide | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 12 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 13 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | 11 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Indomethacin | Indomethacin | 23 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | 11 |
| Linzess | Linaclotide | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | 11 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Nystatin | Nystatin | 11 | 11 |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $469.01 · 23 records | Inspire Medical Systems, Inc. | AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, Doc Band, ELIQUIS, INSPIRE, JARDIANCE, KISUNLA, Kerendia, Natroba, SHINGRIX, Spinosad, TRELEGY ELLIPTA, UBRELVY, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error